Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Adam J. Schoenfeld"'
Autor:
Adam J. Schoenfeld, Hira A. Rizvi, Danish Memon, Narek Shaverdian, Matthew J. Bott, Jennifer L. Sauter, C. Jillian Tsai, Jayon Lihm, David Hoyos, Andrew J. Plodkowski, Rocio Perez-Johnston, Peter Sawan, Jacklynn V. Egger, Benjamin D. Greenbaum, Andreas Rimner, Gregory J. Riely, Charles M. Rudin, Valerie W. Rusch, Daniel R. Gomez, Matthew D. Hellmann
Publikováno v:
Clinical Cancer Research. 28:3797-3803
Purpose: Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. Experimental Design: All cases of metastatic lung cancer treated with PD-(L)1 blockade at Memorial Sloan Kettering were
Autor:
Sudarshan R. Iyer, Igor Odintsov, Adam J. Schoenfeld, Evan Siau, Marissa S. Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J. Riely, Marc Ladanyi, Romel Somwar, Monika A. Davare
Publikováno v:
Mol Cancer Res
Targeted therapy of ROS1-fusion-driven non–small cell lung cancer (NSCLC) has achieved notable clinical success. Despite this, resistance to therapy inevitably poses a significant challenge. MYC amplification was present in ∼19% of lorlatinib-res
Autor:
Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J. Schoenfeld, Helena A. Yu, Gregory J. Riely, Shinichi Toyooka, Christine M. Lovly, Paul Paik, Marc Ladanyi, Pang-Dian Fan
Publikováno v:
JCO Precision Oncology.
PURPOSE The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential role of YES1 amplification as a
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Alexander Drilon, David Hoyos, M. Offin, Jia Luo, Paul K. Paik, A. Iqbal, Chaitanya Bandlamudi, Kathryn C. Arbour, Matthew D. Hellmann, Marjorie G. Zauderer, Benjamin D. Greenbaum, Marta Łuksza, Mark T.A. Donoghue, Kenneth K.-S. Ng, Bob T. Li, R.M. Daly, Adam J. Schoenfeld, Hira Rizvi, Helena A. Yu, Isabel Ruth Preeshagul, Caroline G. McCarthy, Jamie E. Chaft, Charles M. Rudin, Gregory J Riely, Juliana Eng, Jacklynn V. Egger, Azadeh Namakydoust, W.V. Lai, Mark G. Kris, Christina Falcon, Piro Lito
Publikováno v:
Annals of Oncology
Structured Abstract Background Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during thi
Autor:
Jennifer L. Sauter, Barry S. Taylor, Andrew J. Plodkowski, Mark T.A. Donoghue, Charles M. Rudin, Adam J. Schoenfeld, Peter Sawan, William D. Travis, Gregory J. Riely, Jacklynn V. Egger, Marc Ladanyi, Kathryn C. Arbour, Matthew D. Hellmann, Amanda Beras, Rocio Perez-Johnston, Natasha Rekhtman, Hira Rizvi, Chaitanya Bandlamudi
Publikováno v:
Ann Oncol
BACKGROUND: PD-L1 expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tu
Autor:
Mrinal M. Gounder, Ni Ai, Natasha Rekhtman, Joseph Montecalvo, Andrew J. Plodkowski, Patrice Desmeules, Amanda Beras, William D. Travis, Marc Ladanyi, Achim A. Jungbluth, Gregory J. Riely, Adam J. Schoenfeld, Justin A. Bishop, Azadeh Namakydoust, Bob T. Li, Deepu Alex, Charles M. Rudin, Jennifer L. Sauter, Brie Kezlarian, Ryan Ptashkin, Jason C. Chang, David R. Jones
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Introduction: Highly aggressive thoracic neoplasms characterized by SMARCA4 (BRG1) deficiency and undifferentiated round cell or rhabdoid morphology have been recently described and proposed to represent thoracic sarcomas. However, it remains unclear
Autor:
Mark G. Kris, Shirish M. Gadgeel, Hira Rizvi, Helena A. Yu, Adam J. Schoenfeld, G. J. Riely, Jeffrey Girshman, A. Iqbal, Kathryn C. Arbour, Matthew D. Hellmann
Publikováno v:
Annals of Oncology
Background Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitor
Autor:
Amin H. Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Habib El-Khoury, Muhieddine Labban, Christopher Fong, Kanika S. Arora, Chris Labaki, Wenxin Xu, Guru Sonpavde, Robert I. Haddad, Kent W. Mouw, Marios Giannakis, F. Stephen Hodi, Noah Zaitlen, Adam J. Schoenfeld, Nikolaus Schultz, Michael F. Berger, Laura E. MacConaill, Guruprasad Ananda, David J. Kwiatkowski, Toni K. Choueiri, Deborah Schrag, Jian Carrot-Zhang, Alexander Gusev
Publikováno v:
Cancer Cell. 40:1161-1172.e5
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the extent to which TMB-high generalizes as an accurate biomarker in divers
Autor:
Scott J. Antonia, F.S. Hodi, Maurice Pérol, Matthew D. Hellmann, Adam J. Schoenfeld, D.S.W. Tan, Scott N. Gettinger, Martin Reck, Melissa Lynne Johnson, Justin F. Gainor, Natasha B. Leighl, Mark M. Awad, Benjamin Solomon, Enriqueta Felip, Tony Mok, Solange Peters, Christine M. Lovly, J-C. Soria
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(12)
Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of